Dr. Michael Quirmbach, Chief Business Officer – CordenPharma International
Click HERE to download the PDF version
ANY UPDATES ON SOME OF YOUR MOST RECENT KEY STRATEGIC INVESTMENT / EXPANSION PROJECTS?
At the end of 2018 we successfully completed our US$20 million flagship investment in CordenPharma Caponago (IT). The construction resulted in our new commercial aseptic fill and finish injectable plant, consisting of two highly flexible filling lines enabling the manufacture of a broad range of vials, Pre-Filled Syringes (PFS) and cartridges using state-of-the-art nest & tub technology. Both lines have been approved by AIFA and one of the new lines is already operational, with a successful PAI FDA inspection for two products. Overall, the two new lines will increase the manufacturing capacity to 20 million units per year and add expanded lyophilization capacity.
Furthermore, we are in the process of compl ... ...